¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : ºÐÀÚ À¯Çüº°, Á¦Ç°º°, ¼ºñ½ºº°, Ä¡·á ºÐ¾ßº°, Åõ¿© °æ·Îº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Sterile Injectables CDMO Market Size, Share & Trends Analysis Report By Molecule Type (Small Molecule, Large Molecule), By Product, By Service, By Therapeutic Area, By Route Of Administration, By End-use, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå
:
1654288
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2025³â 01¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 180 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå µ¿Çâ:
¼¼°è ¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå ±Ô¸ð´Â 2024³â 42¾ï 5,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2025³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 9.61%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀº ÁÖ»çÁ¦ ÆÄÀÌÇÁ¶óÀΰú ½ÂÀÎ Áõ°¡ÀÔ´Ï´Ù. Á¦¾à»çµéÀº ºü¸¥ ¾àÈ¿ ¹ßÇö, Á¤È®ÇÑ Åõ¾à, ȯÀÚÀÇ º¹¾à ¼øÀÀµµ Çâ»ó µî ´Ù¾çÇÑ ÀåÁ¡À» °¡Áø ÁÖ»çÁ¦ °³¹ß¿¡ Àû±Ø ³ª¼°í ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î, 2024³â 1¿ù¿¡ ¹ßÇ¥µÈ ¹Ì±¹ ½ÄǰÀǾ౹(FDA)ÀÇ º¸°í¼¿¡ µû¸£¸é, ÀǾàǰÆò°¡¿¬±¸¼¾ÅÍ(CDER)´Â 2023³â¿¡ 55°³ÀÇ ½Å¾àÀ» ½ÂÀÎÇß½À´Ï´Ù. ÀÌ ÀǾàǰ¿¡´Â ÁÖ»çÁ¦µµ Æ÷ÇԵǾî ÀÖ¾î °·ÂÇÑ ÆÄÀÌÇÁ¶óÀÎÀÌ ÀÖÀ½À» º¸¿©ÁÝ´Ï´Ù. ÀÌ ÆÄÀÌÇÁ¶óÀÎÀº »ó¾÷Àû ¸ñÀû°ú ¿¬±¸ ¸ñÀû ¸ðµÎ¿¡¼ À§Å¹ Á¦Á¶ ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¸¦ ÃËÁøÇÏ¿© Àüü ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼¼Æ÷ Ä¡·áÁ¦ ¹× À¯ÀüÀÚ Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. Ä¡·áÁ¦ ÆÄÀÌÇÁ¶óÀÎÀÌ È®´ëµÊ¿¡ µû¶ó À§Å¹»ý»ê±â°ü(CMO)ÀÌ Á¦°øÇÏ´Â Àü¹®Àû Á¦Á¶ ¿ª·®¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ À¯ÀüÀÚ ¹× ¼¼Æ÷ Ä¡·áÇÐȸ(ASGCT)¿¡ µû¸£¸é, ÇöÀç 3,866°³ÀÇ Ä¡·á¹ýÀÌ °³¹ß ÁßÀ̸ç, ±× ¹üÀ§´Â ÀüÀÓ»ó ´Ü°èºÎÅÍ µî·Ï Àü ´Ü°è±îÁö ´Ù¾çÇÕ´Ï´Ù. ÀÌ Áß 2,082°³ÀÇ Ä¡·á¹ýÀÌ À¯ÀüÀÚ Ä¡·á·Î ºÐ·ùµÇ¸ç, CAR T ¼¼Æ÷ Ä¡·á¿Í °°Àº À¯ÀüÀÚ º¯Çü ¼¼Æ÷ Ä¡·á°¡ Æ÷ÇԵǾî À¯ÀüÀÚ, ¼¼Æ÷, RNA Ä¡·áÀÇ 53%¸¦ Â÷ÁöÇÕ´Ï´Ù. ¶ÇÇÑ, 862°³ÀÇ Ä¡·á¹ýÀº ºñÀ¯ÀüÀÚÀçÁ¶ÇÕ¼¼Æ÷ Ä¡·áÁ¦·Î Àüü °³¹ß ÁßÀÎ À¯ÀüÀÚ, ¼¼Æ÷, RNA Ä¡·á¹ýÀÇ 22%¸¦ Â÷ÁöÇÕ´Ï´Ù. ÀÌó·³ °·ÂÇÑ Á¦Ç° ÆÄÀÌÇÁ¶óÀΰú ÷´Ü Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â Àüü ½ÃÀå ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
½ÃÀå ÁøÀÔ ±â¾÷µéÀº ¹«±Õ Á¦Á¶ ½Ã¼³ÀÇ È®Àå, °øµ¿ ¿¬±¸ ¹× Á¦ÈÞ¿Í °°Àº Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê¸¦ ÃëÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 3¿ù, Alcami CorporationÀº Tanvex CDMO¿Í ÆÄÆ®³Ê½ÊÀ» ü°áÇÏ¿© »ý¹°ÇÐÀû Á¦Á¦ Á¦Á¶ ¿ª·®À» °ÈÇßÀ¸¸ç, Alcami´Â ¹«±Õ ÃæÀü, ¶óº§¸µ ¹× Æ÷Àå¿¡ ´ëÇÑ Àü¹® Áö½ÄÀ» Ȱ¿ëÇϰí Tanvex´Â °í󸮷® ¿ø·áÀǾàǰ °³¹ß ¼ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù. À̹ø ÆÄÆ®³Ê½ÊÀº Ư¼ö Ä¡·áÁ¦ ¹× º¹ÀâÇÑ »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇÏ°í ¹«±Õ ÁÖ»çÁ¦ °ø±ÞÀ» °¡¼ÓÈÇϱâ À§ÇÑ °ÍÀÔ´Ï´Ù.
¹«±Õ ÁÖ»çÁ¦¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä´Â Á¦Á¶ À§Å¹¾÷ü¿Í ¹ÙÀÌ¿À Á¦¾à ȸ»ç °£ÀÇ ¾Æ¿ô¼Ò½Ì °è¾àÀÇ ¼ºÀåÀ» ÃËÁøÇÏ°í ¹«±Õ ÁÖ»çÁ¦ CDMO »ê¾÷ÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ºü¸¥ ¾àÈ¿, ºü¸¥ Èí¼ö, ³·Àº ¾à¹° ³óµµ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ¹«±Õ ÁÖ»çÁ¦ CDMO »ê¾÷ÀÇ Ã¤Åÿ¡ ±â¿©ÇÏ´Â ¸î °¡Áö ÁÖ¿ä Ãø¸éÀÔ´Ï´Ù. ¶ÇÇÑ, ¹«±Õ ÁÖ»çÁ¦ °³¹ß ¹× Á¦Á¶¿¡ Àû±ØÀûÀ¸·Î Âü¿©ÇÏ´Â Á¦¾à ȸ»ç´Â ´ÜŬ·ÐÇ×ü ¿ä¹ý, °íºÐÀÚ ÁÖ»çÁ¦, °¨¿°¼º Áúȯ Ä¡·áÁ¦¸¦ Áö¿øÇϱâ À§ÇØ °ßÀηÂÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. Á¦³×¸¯ ÁÖ»çÁ¦ÀÇ ¿¬±¸ °³¹ß Áֱ⠴ÜÃà ¹× ºñ¿ë Àý°¨, Èñ±Í Áúȯ Ä¡·áÀÇ ¹ßÀü µî ¿©·¯ °¡Áö ¿äÀÎÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈÇϰí ÀÖ½À´Ï´Ù.
¾Ï Ä¡·áÁ¦ÀÇ ¾ÈÁ¤¼º°ú À¯È¿¼ºÀ» È®º¸Çϱâ À§Çؼ´Â °íµµÀÇ Á¦Á¶ ±â¼úÀÌ ÇʼöÀûÀÔ´Ï´Ù. ¹«±ÕÁÖ»çÁ¦ Àü¹® À§Å¹Á¦Á¶¾÷ü, ƯÈ÷ º¹ÀâÇÑ Á¦Á¦ ¹× »ý¹°ÇÐÀû Á¦Á¦ Ãë±Þ °æÇèÀÌ Ç³ºÎÇÑ Á¦Á¶¾÷ü´Â ¾Ï Ä¡·áÁ¦ÀÇ Æ¯¼öÇÑ ¿ä±¸»çÇ׿¡ ´ëÀÀÇÒ ¼ö Àִ üÁ¦¸¦ °®Ãß°í ÀÖ½À´Ï´Ù. ¹«±Õ ÁÖ»çÁ¦´Â ¾Ï Ä¡·á¿¡¼ º¹ÀâÇÑ »ý¹°ÇÐÀû Á¦Á¦ ¹× Çõ½ÅÀûÀÎ Ä¡·á¹ýÀ» Á¦°øÇÏ´Â µ¥ ÇʼöÀûÀ̸ç, ¹«±Õ ÁÖ»çÁ¦ À§Å¹ Á¦Á¶ ºÎ¹®ÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¾Æ¿ô¼Ò½ÌÀÇ È®´ë´Â ¿¹Ãø ±â°£ µ¿¾È ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¦¾à»ç, ƯÈ÷ ¾Ï ºÐ¾ß¿¡ Æ¯ÈµÈ Á¦¾à»çµéÀº ÇÁ·Î¼¼½º °£¼ÒÈ, ºñ¿ë Àý°¨, Á¦Á¶ À§Å¹¾÷ü°¡ Á¦°øÇÏ´Â Àü¹® Áö½Ä Ȱ¿ëÀ» À§ÇØ Á¦Á¶ ¾Æ¿ô¼Ò½ÌÀ¸·Î ´«À» µ¹¸®°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È´Â ¾Ï ºÐ¾ß ¹«±Õ ÁÖ»çÁ¦ °³¹ß ¹× Á¦Á¶ À§Å¹ ½ÃÀåÀ» ´«¿¡ ¶ç°Ô ¼ºÀå½Ã۰í ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
½ÃÀå °èÅë Àü¸Á
»óºÎ ½ÃÀå Àü¸Á
º¸Á¶ ½ÃÀå Àü¸Á
½ÃÀå ¿ªÇÐ
½ÃÀå µå¶óÀ̹ö ºÐ¼®
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
±â¼úÀÇ Áøº¸
°¡°Ý ¸ðµ¨ ºÐ¼®
ÀÓ»ó½ÃÇè º¼·ý ºÐ¼®, 2023³â
Áö¿ªº° ÀÓ»ó½ÃÇè ÃѼö(2023³â)
ÀÓ»ó½ÃÇè ÃѼö(´Ü°èº°)(2023³â)
ÀÓ»ó½ÃÇè ÃѼö(¿¬±¸ µðÀÚÀκ°)(2023³â)
ÁÖ¿ä Ä¡·á ºÐ¾ßº° ÀÓ»ó½ÃÇè ÃѼö(2023³â)
¸ê±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå : ºÐ¼® Åø
Porter's Five Forces ºÐ¼®
PESTEL ºÐ¼®
COVID-19ÀÇ ¿µÇ⠺м®
Á¦4Àå ¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå : ºÐÀÚ À¯Çü ÃßÁ¤¡¤µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼¼°èÀÇ ¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå º¯µ¿ ºÐ¼®
¼¼°èÀÇ ¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ºÐÀÚ À¯Çüº°, 2018³â¿¡¼ 2030³â
¼ÒºÐÀÚ
°Å´ë ºÐÀÚ
Á¦5Àå ¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå : Á¦Ç° ÃßÁ¤¡¤µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼¼°èÀÇ ¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå º¯µ¿ ºÐ¼®
¼¼°èÀÇ ¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, Á¦Ç°º°, 2018³â¿¡¼ 2030³â
ÇÁ¸®ÇÊµå ½Ã¸°Áö
¹ÙÀ̾˰ú ¾ÚÇÃ
Ư¼ö ÁÖ»çÁ¦
±âŸ
Á¦6Àå ¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå : ¼ºñ½º ÃßÁ¤¡¤µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼¼°èÀÇ ¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå º¯µ¿ ºÐ¼®
¼¼°èÀÇ ¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¼ºñ½ºº°, 2018³â¿¡¼ 2030³â
ó¹æ °³¹ß
ºÐ¼® ¹× ½ÃÇè ¼ºñ½º
¹æ¹ý °³¹ß°ú °ËÁõ
¾ÈÁ¤¼º Å×½ºÆ®
ÃßÃ⡤ħÃâ ½ÃÇè
±âŸ
Á¦Á¶¾÷
ÀÓ»ó½ÃÇè Á¦Á¶
»ó¾÷ Á¦Á¶¾÷
¹«±Õ ÃæÀü ¹× ¿ÏÁ¦ ¼ºñ½º
ÆÐŰ¡
º¸°ü
±âŸ
Á¦7Àå ¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå : Ä¡·á ºÐ¾ß ÃßÁ¤¡¤µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼¼°èÀÇ ¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå Ä¡·á ºÐ¾ß º¯µ¿ ºÐ¼®
¼¼°èÀÇ ¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, Ä¡·á ºÐ¾ß, 2018³â¿¡¼ 2030³â
Á¾¾çÇÐ
½ÉÇ÷°üÁúȯ
ÁßÃ߽Űæ°è Áúȯ
°¨¿°Áõ
±Ù°ñ°Ý°è Áúȯ
È£¸£¸óÁúȯ
±âŸ
Á¦8Àå ¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå : Åõ¿© °æ·Î ÃßÁ¤¡¤µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼¼°èÀÇ ¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå Åõ¿© °æ·Î º¯µ¿ ºÐ¼®
¼¼°èÀÇ ¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, Åõ¿© °æ·Î, 2018³â¿¡¼ 2030³â
ÇÇÇÏ(SC)
Á¤¸Æ³»(IV)
±ÙÀ°³»(IM)
±âŸ
Á¦9Àå ¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ¸ð´Þ¸®Æ¼ ÃßÁ¤¡¤µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼¼°èÀÇ ¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
¼¼°èÀÇ ¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ÃÖÁ¾ ¿ëµµ, 2018³â¿¡¼ 2030³â
Á¦¾àȸ»ç
¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷
±âŸ
Á¦10Àå ¹«±Õ ÁÖ»çÁ¦ CDMO ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®
Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â ¹× 2030³â
Áö¿ª ½ÃÀå ´ë½Ãº¸µå
ºÏ¹Ì
À¯·´
¿µ±¹
µ¶ÀÏ
ÇÁ¶û½º
ÀÌÅ»¸®¾Æ
½ºÆäÀÎ
µ§¸¶Å©
½º¿þµ§
³ë¸£¿þÀÌ
¾Æ½Ã¾ÆÅÂÆò¾ç
ÀϺ»
Áß±¹
Àεµ
Çѱ¹
È£ÁÖ
ű¹
º£Æ®³²
Àεµ³×½Ã¾Æ
¸»·¹À̽þÆ
Çʸ®ÇÉ
½Ì°¡Æ÷¸£
¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
³²¾ÆÇÁ¸®Ä«°øÈ±¹
»ç¿ìµð¾Æ¶óºñ¾Æ
¾Æ¶ø¿¡¹Ì¸®Æ®
Äí¿þÀÌÆ®
Á¦11Àå °æÀï ±¸µµ
½ÃÀå ÁøÃâ ±â¾÷ ºÐ·ù
¼ºñ½º È÷Æ®¸Ê ºÐ¼®(±â¾÷³¢¸®ÀÇ ºñ±³ ºÐ¼®)
±â¾÷ °³¿ä
Boehringer Ingelheim International GmbH
Baxter Simtra Bio Pharma Solutions
Vetter Pharma International GmbH
Recipharm AB
Aenova Group
Fresenius Kabi Contract Manufacturing(Fresenius Kabi AG)
Unither Pharmaceuticals
FAMAR Health Care Services
Ajinomoto Bio-Pharma
PCI Pharma Services
IDT Biologika GmbH
Alcami Corporation
Fareva Group
Eurofins Scientific
Siegfried AG
Torbay Pharmaceuticals
Pfizer CentreOne(Pfizer Inc)
ksm
¿µ¹® ¸ñÂ÷
Sterile Injectables CDMO Market Trends:
The global sterile injectables CDMO market size was estimated at USD 4.25 billion in 2024 and is projected to grow at a CAGR of 9.61% from 2025 to 2030. The market growth is primarily driven by increasing pipeline and approvals of injectable drugs. Pharmaceutical companies are proactively focusing on developing injectable medications due to their numerous benefits, such as quicker onset of action, precise dosing, and enhanced patient adherence.
For instance, as per the U.S. Food and Drug Administration (FDA) report published in January 2024, the Center for Drug Evaluation and Research (CDER) approved 55 novel drugs in 2023. These medications included injectables, indicating a robust pipeline that is anticipated to drive an increase in the demand for contract manufacturing services for both commercial and research purposes, hence contributing to overall market growth.
The increasing demand for cellular and genetic therapies is driving the market's growth. With the expansion of therapy pipelines, there is a rising requirement for specialized manufacturing capabilities provided by contract manufacturing organizations (CMOs). For instance, according to the American Society of Gene & Cell Therapy (ASGCT), 3,866 therapies are currently in development, spanning from preclinical stages through preregistration. Within this landscape, 2,082 therapies are categorized as gene therapies, which include genetically modified cell therapies like CAR T-cell therapies, constituting 53% of gene, cell, and RNA therapies. In addition, 862 therapies are nongenetically modified cell therapies, making up 22% of the overall gene, cell, and RNA therapies in development. Thus, a strong product pipeline and growing demand for advanced therapeutics are likely to enhance overall market demand.
Strategic initiatives undertaken by market participants, such as expanding sterile manufacturing facilities and engaging in collaborations and partnerships, are anticipated to bolster market growth throughout the projected period. For instance, in March 2024, Alcami Corporation company partnered with Tanvex CDMO, enhancing its capabilities in biologics manufacturing. Alcami would leverage its expertise in sterile filling, labeling, and packaging, while Tanvex would contribute its high-throughput bulk drug substance development services. The partnership aimed to expedite the delivery of sterile injectables, addressing the increasing demand for specialty therapeutics and complex biologics.
The high demand for sterile injectables propels growth in outsourced agreements amongst contract manufacturers and biopharmaceutical companies, thereby boosting the growth of the sterile injectable CDMO industry. The growing need for faster drug action, rapid absorption, and less drug concentration are a few major aspects contributing to the adoption of sterile injectables CDMO industry. Further, pharmaceutical firms actively involved in sterile injectable development and manufacturing are gaining traction to support monoclonal antibody therapies, large-molecule injectable drugs, and infectious disease-treating drugs. Several factors, including reduced time and cost-affordable research and development cycles of generic injectables and the growing advancements in rare disease treatments, are accelerating the market growth.
Advanced manufacturing techniques are crucial for ensuring the stability and efficacy of cancer therapies. Contract manufacturers specializing in sterile injectables, particularly those experienced in handling complex formulations and biologics, are well-equipped to address the specific requirements of oncology drugs. Sterile injectables are essential for delivering complex biologics and innovative treatment methods in cancer treatment, driving the growth of the sterile injectable contract manufacturing sector. The growth in outsourcing practices is expected to drive the expansion of the segment over the forecast period. Pharmaceutical companies, particularly those specializing in oncology, are increasingly turning to outsourcing manufacturing operations to streamline processes, cut costs, and capitalize on the specialized expertise offered by contract manufacturers. This shift has notably boosted the cancer sector's sterile injectable contract development and manufacturing market.
Global Sterile Injectables CDMO Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global sterile injectables CDMO market report based on molecule type, product, service, therapeutic area, route of administration, end-use, and region.
Molecule Type Outlook (Revenue, USD Million, 2018 - 2030)
Small Molecule
Large Molecule
Product Outlook (Revenue, USD Million, 2018 - 2030)
Pre-filled Syringes
Vials and Ampoules
Specialty Injectables
Others
Service Outlook (Revenue, USD Million, 2018 - 2030)
Formulation Development
Analytical and Testing Services
Method Development and Validation
Stability Testing
Drug Substance
Stability Indicating Method Validation
Accelerated Stability Testing
Photostability Testing
Other Stability Testing Methods
Extractable & Leachable Testing
Others
Manufacturing
Clinical Trial Manufacturing
Commercial Manufacturing
Aseptic Fill-Finish Services
Packaging
Storage
Others
Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
Oncology
Cardiovascular Diseases
Central Nervous System Diseases
Infectious Disorders
Musculoskeletal Diseases
Hormonal Diseases
Others
Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
Subcutaneous (SC)
Intravenous (IV)
Intramuscular (IM)
Others
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical Companies
Biopharmaceutical Companies
Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Latin America
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definition
1.2.1. Molecule Type
1.2.2. Product
1.2.3. Service
1.2.4. Therapeutic Area
1.2.5. Route of Administration
1.2.6. End Use
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR's Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.6.1. Region Wise Market: Base Estimates
1.6.2. Global Market: CAGR Calculation
1.7. Model Details
1.7.1. Commodity Flow Analysis (Model 1)
1.7.2. Value-Chain-Based Sizing & Forecasting (Model 2)
1.7.3. QFD Model Sizing & Forecasting (Model 3)
1.7.4. Bottom-Up Approach (Model 4)
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Sterile Injectables CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Pipeline and Approvals of Injectables
3.2.1.2. Growing Demand for Biologics and Biosimilars Significantly Supported Market Growth
3.2.1.3. Rise in Investment Across Research & Development Activities for the Development of Novel Therapeutics
3.2.1.4. Increasing Demand for One-stop-shop CDMOs
3.2.1.5. Increasing Outsourcing Services by Pharmaceutical Companies
3.2.2. Market Restraint Analysis
3.2.2.1. Low Barriers to Market Penetration Have Resulted in Pricing Pressure
3.2.2.2. Challenges Related to Quality Control
3.2.2.3. Compliance issues while outsourcing
3.2.2.4. Contractual Obligation
3.3. Technological Advancements
3.4. Pricing Model Analysis
3.5. Clinical Trials Volume Analysis, 2023
3.5.1. Total Number of Clinical Trials, by Region (2023)
3.5.2. Total Number of Clinical Trials, by Phase (2023)
3.5.3. Total Number of Clinical Trials, by Study Design (2023)
3.5.4. Total Number of Clinical Trials, by Key Therapeutic Area (2023)
3.6. Sterile Injectables CDMO Market: Analysis Tools
3.6.1. Porter's Five Forces Analysis
3.6.2. PESTEL Analysis
3.7. COVID-19 Impact Analysis
Chapter 4. Sterile Injectables CDMO Market: Molecule Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Sterile Injectables CDMO Market Movement Analysis
4.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, by Molecule Type, 2018 to 2030 (USD Million)
4.4. Small Molecule
4.4.1. Small Molecule Market Estimates and Forecast, 2018 to 2030 (USD Million)
4.5. Large Molecule
4.5.1. Large Molecule Market Estimates and Forecast, 2018 to 2030 (USD Million)
Chapter 5. Sterile Injectables CDMO Market: Product Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Sterile Injectables CDMO Market Movement Analysis
5.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
5.4. Pre-filled Syringes
5.4.1. Pre-filled Syringes Market Estimates and Forecast, 2018 to 2030 (USD Million)
5.5. Vials and Ampoules
5.5.1. Vials and Ampoules Market Estimates and Forecast, 2018 to 2030 (USD Million)
5.6. Specialty Injectables
5.6.1. Specialty Injectables Market Estimates and Forecast, 2018 to 2030 (USD Million)
5.7. Others
5.7.1. Others Market Estimates and Forecast, 2018 to 2030 (USD Million)
Chapter 6. Sterile Injectables CDMO Market: Service Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Sterile Injectables CDMO Market Movement Analysis
6.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
6.4. Formulation Development
6.4.1. Formulation Development Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.5. Analytical and Testing Services
6.5.1. Analytical and Testing Services Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.5.2. Method Development and Validation
6.5.2.1. Method Development and Validation Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.5.3. Stability Testing
6.5.3.1. Stability Testing Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.5.3.2. Drug Substance
6.5.3.2.1. Drug Substance Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.5.3.3. Stability Indicating Method Validation
6.5.3.3.1. Stability Indicating Method Validation Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.5.3.4. Accelerated Stability Testing
6.5.3.4.1. Accelerated Stability Testing Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.5.3.5. Photostability Testing
6.5.3.5.1. Photostability Testing Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.5.3.6. Other Stability Testing Methods
6.5.3.6.1. Other Stability Testing Methods Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.5.4. Extractable & Leachable Testing
6.5.4.1. Extractable & Leachable Testing Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.5.5. Others
6.5.5.1. Others Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.6. Manufacturing
6.6.1. Manufacturing Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.6.2. Clinical Trial Manufacturing
6.6.2.1. Clinical Trial Manufacturing Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.6.3. Commercial Manufacturing
6.6.3.1. Commercial Manufacturing Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.6.4. Aseptic Fill-Finish Services
6.6.4.1. Aseptic Fill-Finish Services Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.7. Packaging
6.7.1. Packaging Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.8. Storage
6.8.1. Storage Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.8.2. Cold
6.8.2.1. Cold Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.8.3. Non-cold
6.8.3.1. Non-cold Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.9. Others
6.9.1. Others Market Estimates and Forecast, 2018 to 2030 (USD Million)
Chapter 7. Sterile Injectables CDMO Market: Therapeutic Area Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Global Sterile Injectables CDMO Market Therapeutic Area Movement Analysis
7.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, Therapeutic Area, 2018 to 2030 (USD Million)
7.4. Oncology
7.4.1. Oncology Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.5. Cardiovascular Diseases
7.5.1. Cardiovascular Diseases Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.6. Central Nervous System Diseases
7.6.1. Central Nervous System Diseases Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.7. Infectious Disorders
7.7.1. Infectious Disorders Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.8. Musculoskeletal Diseases
7.8.1. Musculoskeletal Diseases Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.9. Hormonal Diseases
7.9.1. Hormonal Diseases Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.10. Others
7.10.1. Others Market Estimates and Forecast, 2018 to 2030 (USD Million)
Chapter 8. Sterile Injectables CDMO Market: Route of Administration Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Global Sterile Injectables CDMO Market Route of Administration Movement Analysis
8.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, Route of Administration, 2018 to 2030 (USD Million)
8.4. Subcutaneous (SC)
8.4.1. Subcutaneous (SC) Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.5. Intravenous (IV)
8.5.1. Intravenous (IV) Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.6. Intramuscular (IM)
8.6.1. Intramuscular (IM) Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.7. Others
8.7.1. Others Market Estimates and Forecast, 2018 to 2030 (USD Million)
Chapter 9. Sterile Injectables CDMO Market: Modality by End Use Estimates & Trend Analysis
9.1. Segment Dashboard
9.2. Global Sterile Injectables CDMO Market End Use Movement Analysis
9.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, End Use, 2018 to 2030 (USD Million)
9.4. Pharmaceutical Companies
9.4.1. Pharmaceutical Companies Market Estimates and Forecast, 2018 to 2030 (USD Million)
9.5. Biopharmaceutical Companies
9.5.1. Biopharmaceutical Companies Market Estimates and Forecast, 2018 to 2030 (USD Million)
9.6. Others
9.6.1. Others Market Estimates and Forecast, 2018 to 2030 (USD Million)
Chapter 10. Sterile Injectables CDMO Market: Regional Estimates & Trend Analysis
10.1. Regional Market Share Analysis, 2024 & 2030
10.2. Regional Market Dashboard
10.3. North America
10.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
10.3.2. U.S.
10.3.2.1. Key Country Dynamics
10.3.2.2. Competitive Scenario
10.3.2.3. Regulatory Framework
10.3.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
10.3.3. Canada
10.3.3.1. Key Country Dynamics
10.3.3.2. Competitive Scenario
10.3.3.3. Regulatory Framework
10.3.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
10.3.4. Mexico
10.3.4.1. Key Country Dynamics
10.3.4.2. Competitive Scenario
10.3.4.3. Regulatory Framework
10.3.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
10.4. Europe
10.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
10.4.2. UK
10.4.2.1. Key Country Dynamics
10.4.2.2. Competitive Scenario
10.4.2.3. Regulatory Framework
10.4.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
10.4.3. Germany
10.4.3.1. Key Country Dynamics
10.4.3.2. Competitive Scenario
10.4.3.3. Regulatory Framework
10.4.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
10.4.4. France
10.4.4.1. Key Country Dynamics
10.4.4.2. Competitive Scenario
10.4.4.3. Regulatory Framework
10.4.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
10.4.5. Italy
10.4.5.1. Key Country Dynamics
10.4.5.2. Competitive Scenario
10.4.5.3. Regulatory Framework
10.4.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
10.4.6. Spain
10.4.6.1. Key Country Dynamics
10.4.6.2. Competitive Scenario
10.4.6.3. Regulatory Framework
10.4.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
10.4.7. Denmark
10.4.7.1. Key Country Dynamics
10.4.7.2. Competitive Scenario
10.4.7.3. Regulatory Framework
10.4.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
10.4.8. Sweden
10.4.8.1. Key Country Dynamics
10.4.8.2. Competitive Scenario
10.4.8.3. Regulatory Framework
10.4.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
10.4.9. Norway
10.4.9.1. Key Country Dynamics
10.4.9.2. Competitive Scenario
10.4.9.3. Regulatory Framework
10.4.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
10.5. Asia Pacific
10.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
10.5.2. Japan
10.5.2.1. Key country dynamics
10.5.2.2. Competitive scenario
10.5.2.3. Regulatory framework
10.5.2.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
10.5.3. China
10.5.3.1. Key country dynamics
10.5.3.2. Competitive scenario
10.5.3.3. Regulatory framework
10.5.3.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
10.5.4. India
10.5.4.1. Key country dynamics
10.5.4.2. Competitive scenario
10.5.4.3. Regulatory framework
10.5.4.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
10.5.5. South Korea
10.5.5.1. Key country dynamics
10.5.5.2. Competitive scenario
10.5.5.3. Regulatory framework
10.5.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
10.5.6. Australia
10.5.6.1. Key country dynamics
10.5.6.2. Competitive scenario
10.5.6.3. Regulatory framework
10.5.6.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
10.5.7. Thailand
10.5.7.1. Key country dynamics
10.5.7.2. Competitive scenario
10.5.7.3. Regulatory framework
10.5.7.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
10.5.8. Vietnam
10.5.8.1. Key country dynamics
10.5.8.2. Competitive scenario
10.5.8.3. Regulatory framework
10.5.8.4. Vietnam market estimates and forecasts, 2018 to 2030 (USD Million)
10.5.9. Indonesia
10.5.9.1. Key country dynamics
10.5.9.2. Competitive scenario
10.5.9.3. Regulatory framework
10.5.9.4. Indonesia market estimates and forecasts, 2018 to 2030 (USD Million)
10.5.10. Malaysia
10.5.10.1. Key country dynamics
10.5.10.2. Competitive scenario
10.5.10.3. Regulatory framework
10.5.10.4. Malaysia market estimates and forecasts, 2018 to 2030 (USD Million)
10.5.11. Philippines
10.5.11.1. Key country dynamics
10.5.11.2. Competitive scenario
10.5.11.3. Regulatory framework
10.5.11.4. Philippines market estimates and forecasts, 2018 to 2030 (USD Million)
10.5.12. Singapore
10.5.12.1. Key country dynamics
10.5.12.2. Competitive scenario
10.5.12.3. Regulatory framework
10.5.12.4. Singapore market estimates and forecasts, 2018 to 2030 (USD Million)
10.6. Latin America
10.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
10.6.2. Brazil
10.6.2.1. Key Country Dynamics
10.6.2.2. Competitive Scenario
10.6.2.3. Regulatory Framework
10.6.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
10.6.3. Argentina
10.6.3.1. Key Country Dynamics
10.6.3.2. Competitive Scenario
10.6.3.3. Regulatory Framework
10.6.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
10.7. MEA
10.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
10.7.2. South Africa
10.7.2.1. Key Country Dynamics
10.7.2.2. Competitive Scenario
10.7.2.3. Regulatory Framework
10.7.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
10.7.3. Saudi Arabia
10.7.3.1. Key Country Dynamics
10.7.3.2. Competitive Scenario
10.7.3.3. Regulatory Framework
10.7.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
10.7.4. UAE
10.7.4.1. Key Country Dynamics
10.7.4.2. Competitive Scenario
10.7.4.3. Regulatory Framework
10.7.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
10.7.5. Kuwait
10.7.5.1. Key Country Dynamics
10.7.5.2. Competitive Scenario
10.7.5.3. Regulatory Framework
10.7.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
Chapter 11. Competitive Landscape
11.1. Market Participant Categorization
11.1.1. Market Leaders
11.1.2. Emerging Players
11.2. Service Heat Map Analysis (a comparative analysis of the players together)
11.3. Company Profiles
11.3.1. Boehringer Ingelheim International GmbH
11.3.1.1. Company Overview
11.3.1.2. Financial Performance
11.3.1.3. Service Benchmarking
11.3.1.4. Strategic Initiatives
11.3.2. Baxter Simtra BioPharma Solutions
11.3.2.1. Company Overview
11.3.2.2. Financial Performance
11.3.2.3. Service Benchmarking
11.3.2.4. Strategic Initiatives
11.3.3. Vetter Pharma International GmbH
11.3.3.1. Company Overview
11.3.3.2. Financial Performance
11.3.3.3. Service Benchmarking
11.3.3.4. Strategic Initiatives
11.3.4. Recipharm AB
11.3.4.1. Company Overview
11.3.4.2. Financial Performance
11.3.4.3. Service Benchmarking
11.3.4.4. Strategic Initiatives
11.3.5. Aenova Group
11.3.5.1. Company Overview
11.3.5.2. Financial Performance
11.3.5.3. Service Benchmarking
11.3.5.4. Strategic Initiatives
11.3.6. Fresenius Kabi Contract Manufacturing (Fresenius Kabi AG)
11.3.6.1. Company Overview
11.3.6.2. Financial Performance
11.3.6.3. Service Benchmarking
11.3.6.4. Strategic Initiatives
11.3.7. Unither Pharmaceuticals
11.3.7.1. Company Overview
11.3.7.2. Financial Performance
11.3.7.3. Service Benchmarking
11.3.7.4. Strategic Initiatives
11.3.8. FAMAR Health Care Services
11.3.8.1. Company Overview
11.3.8.2. Financial Performance
11.3.8.3. Service Benchmarking
11.3.8.4. Strategic Initiatives
11.3.9. Ajinomoto Bio-Pharma
11.3.9.1. Company Overview
11.3.9.2. Financial Performance
11.3.9.3. Service Benchmarking
11.3.9.4. Strategic Initiatives
11.3.10. PCI Pharma Services
11.3.10.1. Company Overview
11.3.10.2. Financial Performance
11.3.10.3. Service Benchmarking
11.3.10.4. Strategic Initiatives
11.3.11. IDT Biologika GmbH
11.3.11.1. Company Overview
11.3.11.2. Financial Performance
11.3.11.3. Service Benchmarking
11.3.11.4. Strategic Initiatives
11.3.12. Alcami Corporation
11.3.12.1. Company Overview
11.3.12.2. Financial Performance
11.3.12.3. Service Benchmarking
11.3.12.4. Strategic Initiatives
11.3.13. Fareva Group
11.3.13.1. Company Overview
11.3.13.2. Financial Performance
11.3.13.3. Service Benchmarking
11.3.13.4. Strategic Initiatives
11.3.14. Eurofins Scientific
11.3.14.1. Company Overview
11.3.14.2. Financial Performance
11.3.14.3. Service Benchmarking
11.3.14.4. Strategic Initiatives
11.3.15. Siegfried AG
11.3.15.1. Company Overview
11.3.15.2. Financial Performance
11.3.15.3. Service Benchmarking
11.3.15.4. Strategic Initiatives
11.3.16. Torbay Pharmaceuticals
11.3.16.1. Company Overview
11.3.16.2. Financial Performance
11.3.16.3. Service Benchmarking
11.3.16.4. Strategic Initiatives
11.3.17. Pfizer CentreOne (Pfizer Inc)
11.3.17.1. Company Overview
11.3.17.2. Financial Performance
11.3.17.3. Service Benchmarking
11.3.17.4. Strategic Initiatives
°ü·ÃÀÚ·á